Biocorrx INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OID
BICX
Biocorrx INCBioCorRx Inc. has acquired a 12.15% stake in its subsidiary, BioCorRx Pharmaceuticals, from key executives and directors in a stock-for-stock exchange.
OID
BICX
Biocorrx INCBioCorRx Inc. has entered into a Securities Purchase Agreement to raise $350,000 by issuing common stock and warrants to accredited investors.
OID
BICX
Biocorrx INCBioCorRx Pharmaceuticals Inc. acquires Lucemyra, an FDA-approved medication for opioid withdrawal, from USWM, LLC to expand its addiction treatment offerings.
OID
BICX
Biocorrx INCBioCorRx Inc. has replaced its independent auditor, Marcum LLP, with M&K CPAS, PLLC, effective July 8, 2024.
OID
BICX
Biocorrx INCBioCorRx Inc. reports the resignation of two board members, Brady Granier and Harsha Murthy, effective March 31, 2024, and April 2, 2024, respectively.